Overview

  • Product name

    Anti-HIV protease antibody
  • Description

    Rabbit polyclonal to HIV protease
  • Host species

    Rabbit
  • Tested applications

    Suitable for: ELISA, WB, IP, Inhibition Assaymore details
  • Species reactivity

    Reacts with: Other species
  • Immunogen

    Recombinant full length protein corresponding to HIV protease. Full-size functional recombinant HIV1 protease expressed and purified from E. coli.
    Database link: P03367

  • Positive control

    • Purified HIV1 Protease; HIV1 (LAI strain) infected MT4 cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab211627 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.
WB 1/2000.
IP 1/200.
Inhibition Assay Use at an assay dependent concentration.

Inhibotion of HIV1 protease activity

Target

  • Relevance

    The HIV1 core consists of a viral genome housed within a conical viral capsid that is generated during virion maturation. Human immunodeficiency virus type 1 (HIV1) matures after the viral protease processes the Gag and Pol polyproteins at 10 substrate locations. The protease of HIV1 is an aspartic protease and is functional only as a dimer; dimerization results in the formation of a binding cleft in which each of the two catalytic aspartic acids in which each monomer contributes each of the 2 catalytic aspartic acids. Because the protease is active only as a dimer, two of the GagPol precursors must themselves dimerize during virus assembly so that their protease domains can dimerize, become active, and process the precursors. Both the order and kinetics of cleavage as well as the extent of precursor processing appear to be critical steps in the generation of fully infectious, appropriately assembled viral particles. Inhibition of HIV-1 protease represents an important avenue for antiviral therapy. Currently available combination chemotherapy with reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) for human immunodeficiency virus type 1 (HIV1) infection and AIDS have been shown to suppress the replication of HIV1 and extend the life expectancy of HIV1 infected individuals.
  • Alternative names

    • HIV-1 protease antibody
    • Human immunodeficiency virus protease antibody
    • PR antibody
    • Retropepsin antibody

Images

  • All lanes : Anti-HIV protease antibody (ab211627) at 1/2000 dilution

    Lane 1 : Purified HIV1 protease at 0.001 µg
    Lane 2 : MT4 cell lysate
    Lane 3 : HIV1 (LAI strain) infected MT4 cell lysate
  • ELISA analysis of purified HIV1 protease using ab211627 at dilutions indicated above the graph

References

ab211627 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab211627.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up